Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Kevin A. Kwei"'
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 6, Iss 5, Pp 440-448 (2004)
Previous studies in our laboratory have shown that the elevation of reactive oxygen species levels and the repression of the antioxidant enzyme, catalase, played a critical role in the in vitro progression of benign papilloma cells to malignant carci
Externí odkaz:
https://doaj.org/article/52b3c77e010645369f07a810da47b702
Autor:
Louis M. Staudt, Amy S. Kimball, Sven de Vos, Jerry Ping, Darrin M. Beaupre, Wyndham H. Wilson, Da-Wei Huang, Kevin A. Kwei, George E. Wright, Leslie Popplewell, Jutta K. Neuenburg, Saurabh Chhabra, Tycel Phillips
Publikováno v:
Leukemialymphoma. 62(9)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is difficult to cure; non-germinal center B-cell-like (non-GCB) and activated B-cell-like (ABC) DLBCL have worse outcomes than GCB DLBCL. Ibrutinib and lenalidomide are synergistic in vitro in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1fb6284c7912a55b4aa5b029c255205
https://pubmed.ncbi.nlm.nih.gov/33856277
https://pubmed.ncbi.nlm.nih.gov/33856277
Autor:
Shiquan Wu, Shuo Ma, Shachar Peles, Israel Arango-Hisijara, Bernhard Hauns, Kevin A. Kwei, Franck Morschhauser, Elizabeth Chong, Morton Coleman, Graham P. Collins, Sven de Vos, Jacqueline C. Barrientos, Stephen D. Smith, Robert T. Chen, Peter Martin, Catherine Thieblemont, Christopher R. Flowers, Leo W.-K. Cheung, Ariela Noy
Publikováno v:
Blood advances. 4(22)
Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c1b58f1fb2d03d2add57f55c2e2c56
https://pubmed.ncbi.nlm.nih.gov/35842643
https://pubmed.ncbi.nlm.nih.gov/35842643
Autor:
Kevin A Kwei, Murali D Bashyam, Jessica Kao, Raman Ratheesh, Edumakanti C Reddy, Young H Kim, Kelli Montgomery, Craig P Giacomini, Yoon-La Choi, Sreejata Chatterjee, Collins A Karikari, Keyan Salari, Pei Wang, Tina Hernandez-Boussard, Gowrishankar Swarnalata, Matt van de Rijn, Anirban Maitra, Jonathan R Pollack
Publikováno v:
PLoS Genetics, Vol 4, Iss 5, p e1000081 (2008)
Pancreatobiliary cancers have among the highest mortality rates of any cancer type. Discovering the full spectrum of molecular genetic alterations may suggest new avenues for therapy. To catalogue genomic alterations, we carried out array-based genom
Externí odkaz:
https://doaj.org/article/221c9acca0d84a9d97a26513cac29146
Autor:
Dan Jones, Kevin A. Kwei, Adrian Wiestner, Danelle F. James, Leo W. K. Cheung, Jennifer A. Woyach, Inhye E. Ahn, James P. Dean, John C. Byrd, Susan O'Brien, Paolo Ghia, Carol Moreno, Elizabeth Chong
Publikováno v:
Blood. 136:32-33
Background : Ibrutinib (Ibr) is the only once-daily Bruton's tyrosine kinase (BTK) inhibitor with significant survival benefit vs chemo- and/or immunotherapy in multiple phase 3 studies of patients (pts) with CLL. Ibr in first-line (1L) CLL is associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a751643a59c42a766fadd26be216915f
https://doi.org/10.1182/blood-2020-134386
https://doi.org/10.1182/blood-2020-134386
Autor:
Sandra Dai, Indu D. Lal, Fatih Demirkan, Talha Munir, David Simpson, Tadeusz Robak, Emily Hsu, Thomas J. Kipps, Leo W. K. Cheung, Alessandra Tedeschi, Don A. Stevens, Jan A. Burger, Osnat Bairey, Carol Moreno, Kevin A. Kwei
Publikováno v:
Blood. 136:25-26
Background Genomic abnormalities such as del(17p)/TP53 mutation, del(11q), and unmutated IGHV are risk factors that predict inferior outcomes with chemoimmunotherapy (CIT) in patients (pts) with CLL/SLL (Byrd J Clin Oncol 2006). Mutations in BIRC3, N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faede0318604423d81bc2c197b9b3fdd
https://doi.org/10.1182/blood-2020-134437
https://doi.org/10.1182/blood-2020-134437
Autor:
Alex F. Herrera, John M. Pagel, Radhakrishnan Ramchandren, Tycel Phillips, Shanhong Guan, Andre Goy, Emily A. Liu, Kevin A. Kwei, Amitkumar Mehta, John S. Hill, Jakub Svoboda
Publikováno v:
American Journal of Hematology
This phase 1b/2, multicenter, open‐label study evaluated ibrutinib plus durvalumab in relapsed/refractory follicular lymphoma (FL) or diffuse large B‐cell lymphoma (DLBCL). Patients were treated with once‐daily ibrutinib 560 mg plus durvalumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aee5aaea2353fdaefa193dc8d6337620
https://pubmed.ncbi.nlm.nih.gov/31621094
https://pubmed.ncbi.nlm.nih.gov/31621094
Autor:
Nicholas Barasch, Xue Gong, Kevin A. Kwei, Nan Xiao, Jonathan R. Pollack, Kunbin Qu, Robert J. Pelham, Joseph S. Lipsick, Robert B. West, Sushama Varma, Jewison Biscocho
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0171265 (2017)
PLoS ONE
PLoS ONE
Pathogenic gene fusions have been identified in several histologic types of salivary gland neoplasia, but not previously in acinic cell carcinoma (AcCC). To discover novel gene fusions, we performed whole-transcriptome sequencing surveys of three AcC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a199fb3017c4f24961b216506cfa895a
http://europepmc.org/articles/PMC5315303?pdf=render
http://europepmc.org/articles/PMC5315303?pdf=render
Autor:
Anita Langerød, Stefanie S. Jeffrey, Dong Young Noh, Jonathan R. Pollack, Anne Lise Børresen-Dale, Wonshik Han, Anna Bergamaschi, Kevin A. Kwei, Yoon-La Choi, Young Ho Kim, Melanie Bocanegra, David G. Huntsman
Publikováno v:
Molecular Oncology. 2:327-339
Breast cancer exhibits clinical and molecular heterogeneity, where expression profiling studies have identified five major molecular subtypes. The basal-like subtype, expressing basal epithelial markers and negative for estrogen receptor (ER), proges
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251381941ac4e4602bcde4a420e93602
https://doi.org/10.1016/j.molonc.2008.09.004
https://doi.org/10.1016/j.molonc.2008.09.004
Autor:
Xue Gong, Kevin A. Kwei, Jonathan R. Pollack, Nicole Clarke, Jean M. Davidson, Jewison Biscocho, Sushmita Sridhar
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 11, p e0142061 (2015)
PLoS ONE, Vol 10, Iss 11, p e0142061 (2015)
NKX2-1, encoding a homeobox transcription factor, is amplified in approximately 15% of non-small cell lung cancers (NSCLC), where it is thought to drive cancer cell proliferation and survival. However, its mechanism of action remains largely unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2317a3970604dafc6376c968cee195db
http://europepmc.org/articles/PMC4640868
http://europepmc.org/articles/PMC4640868